Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty
- PMID: 3292562
- DOI: 10.1210/jcem-67-2-368
Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty
Abstract
To determine whether puberty resumes normally after long term LHRH agonist (LHRHa) treatment, we studied 16 children with central precocious puberty treated with LHRHa (D-Trp6,Pro9,NEt-LHRH) for 1-4 yr (mean, 3.3 yr). Treatment was discontinued at a mean age of 11.6 +/- 1.3 (+/- SD) yr. Plasma hormone levels, growth velocity, rate of bone maturation, and pubertal stage were assessed at the end of treatment and 3 and 12 months later. Basal plasma sex steroid and basal and LHRH-stimulated gonadotropin levels returned to near-pretreatment levels 3 months after discontinuation of therapy and were fully restored to pretreatment levels at 12 months. Growth velocity, which had been 7.8 cm/yr before treatment, was stable after discontinuation of treatment at approximately 2.6 cm/yr. The predicted height, which had increased during treatment (P less than 0.01), remained stable at approximately 5 cm above the pretreatment predicted height. The rate of bone age advancement (delta bone age/delta chronological age) increased gradually from 0.4 at the end of treatment to the normal value of 0.9 12 months posttreatment. Breast and pubic hair pubertal stages, which were stable throughout treatment and were 4.0 +/- 0.8 (+/- SD) and 3.6 +/- 1.0 at the end of treatment, increased to 4.9 +/- 0.2 and 4.5 +/- 1.0. This approximated the normal rate of 1 stage/yr. Menses occurred in 8 of 12 girls within 1 yr after treatment and in an additional 3 by 20 months after treatment. Six of the girls had menstruated before treatment, and all of these menstruated within 14 months after discontinuing therapy. We conclude that gonadotropin and sex steroid secretion and the clinical progression through puberty appear to resume normally after discontinuation of long term LHRHa treatment of central precocious puberty. Long term follow-up will be required, however, to determine whether the improvement in predicted height of these patients will be achieved, and whether adult reproductive function will be normal.
Similar articles
-
Adult height in precocious puberty after long-term treatment with deslorelin.J Clin Endocrinol Metab. 1991 Dec;73(6):1235-40. doi: 10.1210/jcem-73-6-1235. J Clin Endocrinol Metab. 1991. PMID: 1955504
-
Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.J Clin Endocrinol Metab. 1985 Jul;61(1):142-51. doi: 10.1210/jcem-61-1-142. J Clin Endocrinol Metab. 1985. PMID: 3923027
-
Somatomedin-C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist.J Clin Endocrinol Metab. 1985 Jul;61(1):152-9. doi: 10.1210/jcem-61-1-152. J Clin Endocrinol Metab. 1985. PMID: 3889035
-
Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.Endocr Rev. 1986 Feb;7(1):24-33. doi: 10.1210/edrv-7-1-24. Endocr Rev. 1986. PMID: 2937629 Review.
-
[Treatment of precocious puberty with an LH-RH agonist (D-TRP6-LH-RH)].J Steroid Biochem. 1989 Oct;33(4B):805-8. doi: 10.1016/0022-4731(89)90497-4. J Steroid Biochem. 1989. PMID: 2532270 Review. French.
Cited by
-
Effect of Concurrent Gonadotropin-Releasing Hormone Agonist Treatment on Dose and Side Effects of Gender-Affirming Hormone Therapy in Adolescent Transgender Patients.Transgend Health. 2019 Oct 29;4(1):300-303. doi: 10.1089/trgh.2018.0061. eCollection 2019. Transgend Health. 2019. PMID: 31663037 Free PMC article.
-
Update on bioethical, medical and fertility issues in gender incongruence during transition age.J Endocrinol Invest. 2023 Sep;46(9):1725-1736. doi: 10.1007/s40618-023-02077-5. Epub 2023 Apr 18. J Endocrinol Invest. 2023. PMID: 37071372 Free PMC article. Review.
-
Pros and cons of GnRHa treatment for early puberty in girls.Nat Rev Endocrinol. 2014 Jun;10(6):352-63. doi: 10.1038/nrendo.2014.40. Epub 2014 Apr 8. Nat Rev Endocrinol. 2014. PMID: 24709660 Review.
-
Clinical uses of gonadotropin-releasing hormone analogues.CMAJ. 1991 Jan 15;144(2):153-8. CMAJ. 1991. PMID: 1986827 Free PMC article. Review.
-
Understanding and Addressing Disinformation in Gender-Affirming Health Care Bans.Transgend Health. 2024 Aug 16;9(4):281-287. doi: 10.1089/trgh.2022.0198. eCollection 2024 Aug. Transgend Health. 2024. PMID: 39385955 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical